SCHEMBL7019257

SCHEMBL7019257

CC(OCn1cnc2cc(N)ccc21)[Si](C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
HSD17B10 Q99714 1/20 0.55
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FGFR1 P11362 2/20 0.40
QPCT Q16769 5/20 0.35
QPCTL Q9NXS2 5/20 0.35
LCK P06239 1/20 0.35
POLB P06746 1/20 0.35
TNF P01375 2/20 0.34
KDM4E B2RXH2 1/20 0.34
RAD52 P43351 1/20 0.34
CNR2 P34972 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
IKZF3 Q9UKT9 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7016871 0.89 MAPT (0.41) MAPTHSD17B10ALDH1A1SMN1; SMN2FGFR1
SCHEMBL7018800 0.84 MAPT (0.35) MAPTHSD17B10ALDH1A1SMN1; SMN2FGFR1
SCHEMBL7475809 0.80 TDP1 (0.53) MAPTSMN1; SMN2TNFCYP11B1CYP11B2
SCHEMBL19848693 0.80 MAPT (0.64) MAPTHSD17B10ALDH1A1SMN1; SMN2FGFR1
SCHEMBL7017433 0.80 LCK (0.40) ALDH1A1QPCTQPCTLLCKKDM4E
SCHEMBL30591188 0.80 MAPT (0.56) MAPTHSD17B10ALDH1A1SMN1; SMN2FGFR1
SCHEMBL7017505 0.79 PKM (0.53) MAPTALDH1A1SMN1; SMN2POLBKDM4E
SCHEMBL7034018 0.77 MAPT (0.64) MAPTHSD17B10ALDH1A1SMN1; SMN2FGFR1
SCHEMBL7018562 0.77 POLB (0.36) MAPTSMN1; SMN2QPCTQPCTLPOLB
SCHEMBL2541710 0.76 POLB (0.37) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed